A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP

Junichi Seike; Toru Sawada; Naoya Kawakita; Yota Yamamoto; Yasuhiro Yuasa; Hiromichi Yamai; Hirokazu Takachi; Takahiro Yoshida; Akira Tangoku

doi:10.1155/2011/715623

International Journal of Surgical Oncology (Jan 2011)

A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP

Junichi Seike,
Toru Sawada,
Naoya Kawakita,
Yota Yamamoto,
Yasuhiro Yuasa,
Hiromichi Yamai,
Hirokazu Takachi,
Takahiro Yoshida,
Akira Tangoku

Affiliations

Junichi Seike: Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima 770-8503, Japan
Toru Sawada: Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima 770-8503, Japan
Naoya Kawakita: Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima 770-8503, Japan
Yota Yamamoto: Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima 770-8503, Japan
Yasuhiro Yuasa: Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima 770-8503, Japan
Hiromichi Yamai: Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima 770-8503, Japan
Hirokazu Takachi: Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima 770-8503, Japan
Takahiro Yoshida: Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima 770-8503, Japan
Akira Tangoku: Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima 770-8503, Japan

DOI: https://doi.org/10.1155/2011/715623
Journal volume & issue: Vol. 2011

Abstract

Read online

Purpose. Docetaxel/5-FU/CDDP (DFP) therapy is a useful treatment for advanced esophageal cancer. However, adverse reactions such as chemotherapy-induced nausea and vomiting (CINV) interfere often with continuation of the chemotherapy. We investigated the efficacy of rikkunshito (TJ-43) on CINV. Methods. Nineteen patients who were going to undergo DFP therapy were enrolled. They were assigned to the following two groups: a TJ-43-treated group and -nontreated group. The following parameters were compared between the 2 groups: (1) the frequency of symptoms occurred, (2) vomiting, nausea, and anorexia score, and (3) QOL score. Results. The incidence of symptoms was lower in the TJ-43-treated group than that in the control group. The nausea score of the TJ-43-treated group was significantly lower than that of the control group. In the QOL score, the mood score and the ADL score decreased significantly in the control group. Conclusion. We recommend TJ-43 administration in patients undergoing DFP chemotherapy.

Published in International Journal of Surgical Oncology

ISSN: 2090-1402 (Print); 2090-1410 (Online)
Publisher: Hindawi Limited
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.hindawi.com/journals/ijso/

About the journal